41.30

0.13% -0.055

Vericel Corp (VCEL)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Vericel Corp stock is traded at $41.30, with a volume of 715.42K. It is down -0.13% in the last 24 hours and up +4.92% over the past month. Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Previous Close:

$41.35

Open:

$41.27

24h Volume:

715.42K

Relative Volume:

1.39

Market Cap:

$2.08B

Revenue:

$226.84M

Net Income/Loss:

$3.55M

P/E Ratio:

589.93

EPS:

0.07

Net Cash Flow:

$-12.02M

1W Performance:

+0.92%

1M Performance:

+4.92%

6M Performance:

-28.97%

1Y Performance:

-14.29%

1-Day Range:

$40.54

$42.12

1-Week Range:

$40.38

$42.92

52-Week Range:

$37.39

$63.00

Vericel Corp Stock (VCEL) Company Profile

Name

Vericel Corp

Sector

Healthcare (1170)

Industry

Biotechnology (667)

Phone

(734) 930-5555

Address

64 SIDNEY ST., CAMBRIDGE, MA

Employee

357

Twitter

@VericelCorp

Next Earnings Date

2024-11-07

Latest SEC Filings

VCEL's Discussions on Twitter

Compare VCEL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VCEL Vericel Corp	41.30	2.06B	226.84M	3.55M	-12.02M	0.07
ONC Beone Medicines Ltd Adr	245.58	26.10B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	442.05	111.96B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	42.96M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.20	6.39B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.28	63.52B	14.09B	4.50B	2.96B	39.28

Vericel Corp Stock (VCEL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-09-24	Initiated	Canaccord Genuity	Buy
Jun-20-24	Initiated	TD Cowen	Buy
Jan-25-24	Upgrade	Truist	Hold → Buy
Aug-08-23	Upgrade	BTIG Research	Neutral → Buy
Nov-10-22	Downgrade	BTIG Research	Buy → Neutral
Nov-09-22	Downgrade	Truist	Buy → Hold
Oct-14-22	Resumed	Stephens	Overweight
Jan-11-21	Downgrade	Oppenheimer	Outperform → Perform
Dec-18-20	Initiated	Stephens	Overweight
Sep-17-20	Initiated	Truist	Buy
Oct-09-19	Initiated	H.C. Wainwright	Buy
Feb-28-19	Downgrade	Needham	Buy → Hold
Aug-08-18	Reiterated	Needham	Buy
Jul-16-18	Upgrade	Ladenburg Thalmann	Neutral → Buy
Apr-04-18	Initiated	Leerink Partners	Outperform
Mar-06-18	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-06-18	Reiterated	Needham	Buy
Mar-05-18	Reiterated	BTIG Research	Buy
Jun-21-17	Initiated	BTIG Research	Buy
Mar-13-17	Reiterated	Needham	Buy
Dec-22-16	Initiated	Piper Jaffray	Overweight
Nov-09-16	Reiterated	Needham	Buy
Apr-05-16	Downgrade	BofA/Merrill	Buy → Neutral
Mar-11-16	Upgrade	Needham	Hold → Buy

View All

Vericel Corp Stock (VCEL) Latest News

May 26, 2025

Bank of America Corp DE Sells 1,579 Shares of Vericel Co. (NASDAQ:VCEL) - Defense World

May 26, 2025

May 25, 2025

Vericel Co. (NASDAQ:VCEL) Stock Position Cut by BNP Paribas Financial Markets - Defense World

May 21, 2025

May 16, 2025

Truist maintains Buy on Vericel shares with $52 target By Investing.com - Investing.com India

May 16, 2025

Truist maintains Buy on Vericel shares with $52 target - Investing.com

May 16, 2025

VCEL to Be Featured in Upcoming Investor Meetings | VCEL Stock N - GuruFocus

May 16, 2025

Brokerages Set Vericel Co. (NASDAQ:VCEL) Price Target at $60.86 - Defense World

May 16, 2025

May 14, 2025

Vericel at BofA Securities Conference: Growth and Innovation in Healthcare By Investing.com - Investing.com India

May 14, 2025

Vericel at BofA Securities Conference: Growth and Innovation in Healthcare - Investing.com Australia

May 14, 2025

Transcript : Vericel Corporation Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 09 - marketscreener.com

May 14, 2025

May 13, 2025

VCEL: Upcoming Meeting and Market Insights | VCEL Stock News - GuruFocus

May 13, 2025

May 11, 2025

First Trust Advisors LP Lowers Stock Holdings in Vericel Co. (NASDAQ:VCEL) - Defense World

May 11, 2025

Vericel Co. (NASDAQ:VCEL) Shares Sold by Tower Research Capital LLC TRC - Defense World

May 11, 2025

May 10, 2025

Vericel Corporation (NASDAQ:VCEL) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025

Vericel (VCEL) Maintains Buy Rating Despite Target Price Adjustm - GuruFocus

May 10, 2025

May 09, 2025

Vericel (VCEL) Maintains Buy Rating Despite Target Price Adjustment | VCEL Stock News - GuruFocus

May 09, 2025